These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 24599269)

  • 1. Sublingual vaccination induces mucosal and systemic adaptive immunity for protection against lung tumor challenge.
    Singh S; Yang G; Schluns KS; Anthony SM; Sastry KJ
    PLoS One; 2014; 9(3):e90001. PubMed ID: 24599269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.
    Singh S; Yang G; Byrareddy SN; Barry MA; Sastry KJ
    Vaccine; 2014 Dec; 32(51):6934-6940. PubMed ID: 25444819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic induction of adaptive antitumor immunity by codelivery of antigen with α-galactosylceramide on exosomes.
    Gehrmann U; Hiltbrunner S; Georgoudaki AM; Karlsson MC; Näslund TI; Gabrielsson S
    Cancer Res; 2013 Jul; 73(13):3865-76. PubMed ID: 23658368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge.
    Krishnan L; Sad S; Patel GB; Sprott GD
    Cancer Res; 2003 May; 63(10):2526-34. PubMed ID: 12750276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.
    Duewell P; Kisser U; Heckelsmiller K; Hoves S; Stoitzner P; Koernig S; Morelli AB; Clausen BE; Dauer M; Eigler A; Anz D; Bourquin C; Maraskovsky E; Endres S; Schnurr M
    J Immunol; 2011 Jul; 187(1):55-63. PubMed ID: 21613613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sublingual injection of microparticles containing glycolipid ligands for NKT cells and subunit vaccines induces antibody responses in oral cavity.
    DeLyria ES; Zhou D; Lee JS; Singh S; Song W; Li F; Sun Q; Lu H; Wu J; Qiao Q; Hu Y; Zhang G; Li C; Sastry KJ; Shen H
    Carbohydr Res; 2015 Mar; 405():87-92. PubMed ID: 25555750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma.
    Bellone M; Cantarella D; Castiglioni P; Crosti MC; Ronchetti A; Moro M; Garancini MP; Casorati G; Dellabona P
    J Immunol; 2000 Sep; 165(5):2651-6. PubMed ID: 10946294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of sublingual administration with a native or denatured protein allergen and adjuvant CpG oligodeoxynucleotides or cholera toxin on systemic T(H)2 immune responses and mucosal immunity in mice.
    Huang CF; Wang CC; Wu TC; Chu CH; Peng HJ
    Ann Allergy Asthma Immunol; 2007 Nov; 99(5):443-52. PubMed ID: 18051215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broadening the Message: A Nanovaccine Co-loaded with Messenger RNA and α-GalCer Induces Antitumor Immunity through Conventional and Natural Killer T Cells.
    Verbeke R; Lentacker I; Breckpot K; Janssens J; Van Calenbergh S; De Smedt SC; Dewitte H
    ACS Nano; 2019 Feb; 13(2):1655-1669. PubMed ID: 30742405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal but not intravenous delivery of the adjuvant α-galactosylceramide permits repeated stimulation of natural killer T cells in the lung.
    Courtney AN; Thapa P; Singh S; Wishahy AM; Zhou D; Sastry J
    Eur J Immunol; 2011 Nov; 41(11):3312-22. PubMed ID: 21818755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of neonatal sublingual vaccination with native or denatured ovalbumin and adjuvant CpG or cholera toxin on systemic and mucosal immunity in mice.
    Huang CF; Wu TC; Chu YH; Hwang KS; Wang CC; Peng HJ
    Scand J Immunol; 2008 Nov; 68(5):502-10. PubMed ID: 18822109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegalovirus-Based Vaccine Expressing a Modified Tumor Antigen Induces Potent Tumor-Specific CD8(+) T-cell Response and Protects Mice from Melanoma.
    Qiu Z; Huang H; Grenier JM; Perez OA; Smilowitz HM; Adler B; Khanna KM
    Cancer Immunol Res; 2015 May; 3(5):536-46. PubMed ID: 25633711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of pH-sensitive fusogenic polymer-modified liposomes co-loaded with antigen and α-galactosylceramide as an anti-tumor vaccine.
    Okazaki S; Iwasaki T; Yuba E; Watarai S
    J Vet Med Sci; 2018 Feb; 80(2):197-204. PubMed ID: 29311431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Provision of granulocyte-macrophage colony-stimulating factor converts an autoimmune response to a self-antigen into an antitumor response.
    Ji Q; Gondek D; Hurwitz AA
    J Immunol; 2005 Aug; 175(3):1456-63. PubMed ID: 16034082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sublingual immunization with nonreplicating antigens induces antibody-forming cells and cytotoxic T cells in the female genital tract mucosa and protects against genital papillomavirus infection.
    Cuburu N; Kweon MN; Hervouet C; Cha HR; Pang YY; Holmgren J; Stadler K; Schiller JT; Anjuère F; Czerkinsky C
    J Immunol; 2009 Dec; 183(12):7851-9. PubMed ID: 19933861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fully Synthetic Invariant NKT Cell-Dependent Self-Adjuvanting Antitumor Vaccines Eliciting Potent Immune Response in Mice.
    Chen PG; Hu HG; Sun ZY; Li QQ; Zhang BD; Wu JJ; Li WH; Zhao YF; Chen YX; Li YM
    Mol Pharm; 2020 Feb; 17(2):417-425. PubMed ID: 31841011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor.
    Ko SY; Ko HJ; Chang WS; Park SH; Kweon MN; Kang CY
    J Immunol; 2005 Sep; 175(5):3309-17. PubMed ID: 16116223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ascophyllan functions as an adjuvant to promote anti-cancer effect by dendritic cell activation.
    Zhang W; Okimura T; Xu L; Zhang L; Oda T; Kwak M; Yu Q; Jin JO
    Oncotarget; 2016 Apr; 7(15):19284-98. PubMed ID: 27008707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
    Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
    J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical evaluation of mRNA trimannosylated lipopolyplexes as therapeutic cancer vaccines targeting dendritic cells.
    Le Moignic A; Malard V; Benvegnu T; Lemiègre L; Berchel M; Jaffrès PA; Baillou C; Delost M; Macedo R; Rochefort J; Lescaille G; Pichon C; Lemoine FM; Midoux P; Mateo V
    J Control Release; 2018 May; 278():110-121. PubMed ID: 29630987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.